Collegium Pharmaceutical, Inc.
COLL Healthcare Drug Manufacturers Specialty & Generic
Collegium Pharmaceutical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $780.6 million, up 23.6% from fiscal 2024. In the quarter to June 2026, revenue grew 6.32%, EPS fell 221.1%, free cash flow fell 2.14% and total debt rose 32.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow COLL
Collegium Pharmaceutical, Inc. (COLL) EV/Sales
As of 16 October 2026, Collegium Pharmaceutical, Inc. (COLL) trades at a EV/Sales of 2.1×. Over the past ten years it has ranged from 0.0× (June 2017) to 38.6× (July 2017); the current reading is higher than 34% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.4× | (4.78%) |
| FY2024 | 2.5× | 1.15% |
| FY2023 | 2.5× | (12.87%) |
| FY2022 | 2.9× | 10.41% |
| FY2021 | 2.6× | 3.85% |
| FY2020 | 2.5× | 39.44% |
| FY2019 | 1.8× | 16.30% |
| FY2018 | 1.5× | (90.26%) |
| FY2017 | 15.8× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.6× | 46.68% |
| Mar 2026 | 1.8× | (25.48%) |
| Dec 2025 | 2.4× | 12.90% |
| Sep 2025 | 2.1× | (1.36%) |
| 36 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLRY Tilray Brands, Inc. compare | 0.6× |
| EVO Evotec AG compare | 0.6× |
| AMPH Amphastar Pharmaceuticals, Inc. compare | 2.0× |
| EOLS Evolus, Inc. compare | 2.1× |
| COLL Collegium Pharmaceutical, Inc. | 2.1× |
| CRON Cronos Group Inc. compare | 2.3× |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 2.8× |
| HROW Harrow, Inc. compare | 4.5× |
| AQST Aquestive Therapeutics, Inc. compare | 7.9× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)